Literature DB >> 20363625

Identification of a novel series of potent RON receptor tyrosine kinase inhibitors.

Stéphane Raeppel1, Frédéric Gaudette, Michael Mannion, Stephen Claridge, Oscar Saavedra, Ljubomir Isakovic, Robert Déziel, Normand Beaulieu, Carole Beaulieu, Isabelle Dupont, Hannah Nguyen, James Wang, A Robert Macleod, Christiane Maroun, Jeffrey M Besterman, Arkadii Vaisburg.   

Abstract

A novel series of N-(3-fluoro-4-(2-substituted-thieno[3,2-b]pyridin-7-yloxy)phenyl)-1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamides targeting RON receptor tyrosine kinase was designed and synthesized. SAR study of the series allowed us to identify compounds possessing either inhibitory activity of RON kinase enzyme in the low nanomolar range with low residual activity against the closely related c-Met or potent dual inhibitory activity against RON and c-Met, with no significant activity against VEGFR2 in both cases. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20363625     DOI: 10.1016/j.bmcl.2010.03.073

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  5 in total

Review 1.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

Review 2.  Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.

Authors:  Ming-Hai Wang; Snehal S Padhye; Sunny Guin; Qi Ma; Yong-qing Zhou
Journal:  Acta Pharmacol Sin       Date:  2010-08-09       Impact factor: 6.150

Review 3.  The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies.

Authors:  Chang Moo Kang; Michele L Babicky; Andrew M Lowy
Journal:  Pancreas       Date:  2014-03       Impact factor: 3.327

4.  The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Qi Ma; Sunny Guin; Snehal S Padhye; Rui-Wen Zhang; Ming-Hai Wang
Journal:  Mol Cancer       Date:  2011-07-12       Impact factor: 27.401

5.  When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?

Authors:  Anne-Marie Baird; David Easty; Monika Jarzabek; Liam Shiels; Alex Soltermann; Sonja Klebe; Stéphane Raeppel; Lauren MacDonagh; Chengguang Wu; Kim Griggs; Michaela B Kirschner; Bryan Stanfill; Daisuke Nonaka; Chandra M Goparaju; Bruno Murer; Dean A Fennell; Dearbhaile M O'Donnell; Martin P Barr; Luciano Mutti; Glen Reid; Stephen Finn; Sinead Cuffe; Harvey I Pass; Isabelle Opitz; Annette T Byrne; Kenneth J O'Byrne; Steven G Gray
Journal:  Front Endocrinol (Lausanne)       Date:  2019-02-26       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.